JSJames Xavier Sotiropoulos

James Xavier Sotiropoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Xavier Sotiropoulos has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Kylie Elizabeth Hunter

    National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia

    6 shared publications
  • Anna Lene Seidler

    Department of Child and Adolescent Psychiatry, University Medical Centre Rostock, Rostock, Germany

    5 shared publications
  • Ju Lee Oei

    Faculty of Medicine, School of Women's and Children's Health University of New South Wales Sydney New South Wales Australia

    5 shared publications
  • Anna Lene Seidler

    NHMRC Clinical Trials Centre; Faculty of Medicine and Health, University of Sydney; Sydney Australia

    4 shared publications
  • Georg M. Schmölzer

    Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

    4 shared publications
  • Jannik Aagerup

    Department of Child and Adolescent Psychiatry, Neurology, Psychosomatics, and Psychotherapy; University Medical Center Rostock; Rostock Germany

    4 shared publications

Latest Publications

  • Open Access

    Therapeutic hypothermia for newborns with hypoxic-ischaemic encephalopathy

    by Anne Fink, Marie T Berg, Roger F Soll, Michelle Fiander, Kylie Hunter, Jannik Aagerup, James Sotiropoulos, Jane Cracknell, Matteo Bruschettini, Anna Lene Seidler

    This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of therapeutic hypothermia (TH) compared to standard care in newborn infants with hypoxic-ischaemic encephalopathy (HIE).


  • Open Access

    State of play in individual participant data meta-analyses of randomised trials: Systematic review and consensus-based recommendations

    by Anna Lene Seidler, Jannik Aagerup, Lily S Nicholson, Kylie E Hunter, Ram Bajpai, Daniel G Hamilton, Thomas Love, Nadine Marlin, David Nguyen, Richard D Riley, et al.

    Background: Individual participant data (IPD) meta-analyses obtain, harmonise and synthesise the raw individual-level data from multiple studies, and are increasingly important in an era of data sharing and personalised medicine to inform clinical practice and policy. Objectives: (1) Describe the landscape of IPD meta-analysis of randomised trials over time; (2) establish current practice in design, conduct, analysis and reporting for pairwise IPD meta-analysis; and (3) derive recommendations to improve the conduct of and methods for future IPD meta-analyses. Design: Part 1: systematic review of all published IPD meta-analyses of randomised trials; Part 2: in-depth review of current methodological practice for pairwise IPD meta-analysis; and Part 3: adapted nominal group technique to derive consensus recommendations for IPD meta-analysis authors, educators and methodologists. Data sources: MEDLINE, Embase, and the Cochrane Database of Systematic Reviews (via the Ovid interface). Eligibility criteria: Part 1: all IPD meta-analyses of randomised trials published before February 2024, evaluating intervention effects and based on a systematic search. Part 2: all pairwise IPD meta-analyses from part 1 published between February 2022 and February 2024. Part 3: Selected panel of experienced IPD meta-analysis authors and/or methodologists. Results: Part 1: We identified 605 eligible IPD meta-analyses published between 1991 and 2024. The number of IPD meta-analyses published per year increased over time until 2019 but has since plateaued to about 60 per year. The most common clinical areas studied were cardiovascular disease (n=113, 19%) and cancer (n=110, 18%). The proportion of IPD meta-analyses published with Cochrane decreased over time from 16% (n=31/196) before 2015 to 3% (n=5/196) between 2021-2024. Part 2: 100 recent pairwise IPD meta-analyses were included in the in-depth review. Most cited PRISMA-IPD (68, 68%) and conducted risk of bias assessments (n=82, 82%), with just under half carrying out subgroup analyses not at risk of aggregation bias (n=36/85, 41%). However, only 33% (n=33) and 29% (n=29) respectively provided a protocol or statistical analysis plan, and only 7% (n=6/82) reported using IPD to inform risk of bias assessments. Part 3: 24 experts participated in a consensus workshop. Key recommendations for improved IPD meta-analyses focused on transparency (prospective registration; published protocols and statistical analysis plans) and maximising value (searching trial registries; obtaining IPD for unpublished evidence; using IPD to address missing data and risk of bias). Methodologists and educators should strengthen dissemination of methods and support capacity building across clinical fields and geographical areas. Conclusions: The application and methodological quality of IPD meta-analyses of randomised trials has increased in the last decade, but shortcomings remain. Implementing our consensus-based recommendations will ensure future IPD meta-analyses generate better evidence for clinical decision making. Study registration: Open Science Framework (1) Summary boxes: What is already known on this topic: IPD meta-analyses of randomised trials are regularly used to inform clinical policy and practice. They can provide better quality data and enable more thorough and robust analyses than standard aggregate data meta-analyses, but are resource-intensive and can be challenging to conduct, leading to variable methodological quality Previous studies that evaluated the conduct of IPD meta-analyses pre-date several major developments, such as the introduction of the PRISMA-IPD reporting guideline. What this study adds: This is the most comprehensive assessment of IPD meta-analyses of randomised trials to date (605 studies), showing an increase in publications over time followed by a recent plateau. The conduct of IPD meta-analysis has improved in recent years including increased use of prospective registration, assessment of risk of bias, appropriate analyses of patient subgroup effects and citing the PRISMA-IPD statement. Many shortcomings remain including (i) insufficient pre-specification of methods such as outcomes and analyses, (ii) sub-standard transparency (including publication of protocols, statistical analysis plans and reporting of analyses), and (iii) failure to gain maximum value of IPD (i.e. include unpublished trials, use the IPD to inform risk of bias and trustworthiness assessments, and address missing data appropriately); expert consensus recommendations are provided for how to address these gaps.

  • Open Access

    Delivery room oxygen titration strategies for resuscitation of preterm infants

    by James X Sotiropoulos, Roger F Soll, Michelle Fiander, Matteo Bruschettini, Ju Lee Oei, Vishal Kapadia, Anna Lene Seidler, Supported by the Cochrane Neonatal Group, Cochrane Sweden

    Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Research objective 1: to assess the effects of different oxygen saturation targets for the delivery room resuscitation of preterm infants. Research objective 2: to assess the effects of different titration strategies for the delivery room resuscitation of preterm infants.


  • Open Access

    Individual participant data informed risk of bias assessments for randomized controlled trials in systematic reviews and meta-analyses

    by James X. Sotiropoulos, Kylie E. Hunter, Jannik Aagerup, Jonathan G. Williams, Sol Libesman, Mason Aberoumand, Angie Barba, Rui Wang, Thomas D. Love, Brittany J. Johnson, et al.


  • Optimal Oxygen Levels for Preterm Infant Resuscitation—Reply

    by James X. Sotiropoulos, Ju Lee Oei, Anna Lene Seidler

    In Reply We thank Bhurawala for their comments regarding heterogeneity in the Network Meta-Analysis of Trials of Initial Oxygen in Preterm Newborns

  • Open Access

    Aspects on Oxygenation in Preterm Infants before, Immediately after Birth, and Beyond

    by James X. Sotiropoulos, Ola D. Saugstad, Ju Lee Oei

    Background: Oxygen is crucial for life but too little (hypoxia) or too much (hyperoxia) may be fatal or cause lifelong morbidity. Summary: In this review, we discuss the challenges of balancing oxygen control in preterm infants during fetal development, the first few minutes after birth, in the neonatal intensive care unit and after hospital discharge, where intensive care monitoring and response to dangerous oxygen levels is more often than not, out of reach with current technologies and services. Key Messages: Appropriate oxygenation is critically important even from before birth, but at no time is the need to strike a balance more important than during the first few minutes after birth, when body physiology is changing at its most rapid pace. Preterm infants, in particular, have a poor control of oxygen balance. Underdeveloped organs, especially of the lungs, require supplemental oxygen to prevent hypoxia. However, they are also at risk of hyperoxia due to immature antioxidant defenses. Existing evidence demonstrate considerable challenges that need to be overcome before we can ensure safe treatment of preterm infants with one of the most commonly used drugs in newborn care, oxygen.


  • Top Cited Papers

    Initial Oxygen Concentration for the Resuscitation of Infants Born at Less Than 32 Weeks’ Gestation

    by James X. Sotiropoulos, Ju Lee Oei, Georg M. Schmölzer, Sol Libesman, Kylie E. Hunter, Jonathan G. Williams, Angela C. Webster, Maximo Vento, Vishal Kapadia, Yacov Rabi, et al.

    Importance: Resuscitation with lower fractional inspired oxygen (FiO2) reduces mortality in term and near-term infants but the impact of this practice on very preterm infants is unclear.Objective: To evaluate the relative effectiveness of initial FiO2 on reducing mortality, severe morbidities, and oxygen saturations (SpO2) in preterm infants born at less than 32 weeks’ gestation using network meta-analysis (NMA) of individual participant data (IPD).Data Sources: MEDLINE, Embase, CENTRAL, CINAHL, ClinicalTrials.gov, and WHO ICTRP from 1980 to October 10, 2023.Study Selection: Eligible studies were randomized clinical trials enrolling infants born at less than 32 weeks’ gestation comparing at least 2 initial oxygen concentrations for delivery room resuscitation, defined as either low (≤0.3), intermediate (0.5-0.65), or high (≥0.90) FiO2.Data Extraction and Synthesis: Investigators from eligible studies were invited to provide IPD. Data were processed and checked for quality and integrity. One-stage contrast-based bayesian IPD-NMA was performed with noninformative priors and random effects and adjusted for key covariates.Main Outcomes and Measures: The primary outcome was all-cause mortality at hospital discharge. Secondary outcomes were morbidities of prematurity and SpO2 at 5 minutes.Results: IPD were provided for 1055 infants from 12 of the 13 eligible studies (2005-2019). Resuscitation with high (≥0.90) initial FiO2 was associated with significantly reduced mortality compared to low (≤0.3) (odds ratio [OR], 0.45; 95% credible interval [CrI], 0.23-0.86; low certainty) and intermediate (0.5-0.65) FiO2 (OR, 0.34; 95% CrI, 0.11-0.99; very low certainty). High initial FiO2 had a 97% probability of ranking first to reduce mortality. The effects on other morbidities were inconclusive.Conclusions and Relevance: High initial FiO2 (≥0.90) may be associated with reduced mortality in preterm infants born at less than 32 weeks’ gestation compared to low initial FiO2 (low certainty). High initial FiO2 is possibly associated with reduced mortality compared to intermediate initial FiO2 (very low certainty) but more evidence is required.


  • Open Access

    Air or Oxygen for Infant Resuscitation: A Prospective Cohort Study of Moderate-Late Preterm Infants Requiring Delivery Room Resuscitation

    by James X. Sotiropoulos, Sheeba Binoy, Thy A.N. Pham, Kylie Yates, Catherine L. Allgood, Ansar Kunjunju, Mark Tracy, John Smyth, Ju Lee Oei

    Introduction: Due to concerns of oxidative stress and injury, most clinicians currently use lower levels of fractional inspired oxygen (FiO2, 0.21–0.3) to initiate respiratory support for moderate to late preterm (MLPT, 32–36 weeks gestation) infants at birth. Whether this practice achieves recommended oxygen saturation (SpO2) targets is unknown. Methods: We aimed to determine SpO2 trajectories of MLPT infants requiring respiratory support at birth. We conducted a prospective, opportunistic, observational study with consent waiver. Preductal SpO2 readings were obtained during the first 10 min of life from infants between 32 and 36 weeks gestation requiring respiratory support in the delivery room. Primary outcome was reaching a minimum SpO2 80% at 5 min of life. The study was prospectively registered (ACTRN12620001252909). Results: A total of 76 eligible infants were recruited between February 2021 and March 2022 from 5 hospitals in Australia. Most (n = 58, 76%) had respiratory support initiated with FiO2 0.21 (range 0.21–1.0) using CPAP (92%). Median SpO2 at 5 min was 81% (interquartile range [IQR] 67–90) and 93% (IQR 86–96) at 10 min. At 5 min, 18/43 (42%) infants had SpO2 below 80% and only 8/43 (19%) reached SpO2 80–85%. Conclusions: Many MLPT infants requiring respiratory support do not achieve recommended SpO2 targets. In very preterm infants, SpO2 <80% at 5 min of life increases risk of death, intraventricular haemorrhage, and neurodevelopmental impairment. The implications on this practice on the health outcomes of MLPT infants are unclear and require further research.


  • Open Access

    Development of the Individual Participant Data (IPD) Integrity Tool for assessing the integrity of randomised trials using individual participant data

    by Ke Hunter, Mason Aberoumand, Sol Libesman, James X Sotiropoulos, Jonathan G Williams, Wentao Li, Jannik Aagerup, Ben W Mol, Rui Wang, Angie Barba, et al.

    Introduction: Increasing concerns about integrity in medical research have prompted the development of tools to detect untrustworthy studies. Existing tools focus on evaluating aggregate or published data, though some trustworthiness issues may only be detected upon scrutiny of individual participant data (IPD). To address this, we developed the IPD Integrity Tool for detecting integrity issues in randomised controlled trials with IPD available. This manuscript describes the development of this tool. Methods: We conducted a literature review to collate and map existing integrity items. These were discussed with an expert advisory group, and agreed items were included in a standardised tool and automated where possible. We piloted this tool in two IPD meta-analyses, and conducted preliminary validation checks on 13 datasets with and without known integrity issues in a blinded manner. Results: The literature review identified 120 integrity items: 54 could be conducted at the publication or aggregate data (AD) level, 48 required IPD, and 18 were possible with aggregate data, but more comprehensive with IPD. Based on these items, an initial reduced tool was developed in a consensus process involving 13 advisors with different backgrounds (countries, profession, education). This initial tool included 11 items across four domains for AD, and 12 items across 8 domains requiring IPD. The tool was iteratively refined throughout piloting on two IPD meta-analyses including a total of 116 trials (73 with IPD, and 43 with only AD available), and preliminary validation using an additional 13 datasets. All five studies with known integrity issues were accurately identified during validation. The final version of the tool included seven domains with 13 items for AD and eight domains with 18 items requiring IPD. Conclusions: The quality of evidence informing health care relies on trustworthy data. This manuscript describes the development of a tool to enable researchers, editors, and other stakeholders to detect integrity issues in randomised trials using IPD. Detailed instructions on the application of this tool will be published subsequently.


  • Open Access

    PROspective Meta‐analysis Of Trials of Initial Oxygen in preterm Newborns (PROMOTION): Protocol for a systematic review and prospective meta‐analysis with individual participant data on initial oxygen concentration for resuscitation of preterm infants

    by James X. Sotiropoulos, Georg M. Schmölzer, Ju Lee Oei, Sol Libesman, Kylie E. Hunter, Jonathan G. Williams, Angela C. Webster, William O. Tarnow‐Mordi, Maximo Vento, Elizabeth Asztalos, et al.

    Background: Clinicians favour low oxygen concentrations when resuscitating preterm infants immediately after birth despite inconclusive evidence to support this practice. Prospective meta‐analysis (PMA) is a novel approach where studies are identified as eligible for inclusion in the meta‐analysis before their results are known.Aims: To explore whether high (60%) or low (30%) oxygen is associated with greater efficacy and safety for the initial resuscitation (immediately after birth) of preterm infants born at <29 weeks' gestation.Methods: We will conduct a prospective meta‐analysis (PMA) with individual participant data (IPD). We will perform a systematic search to identify ongoing RCTs including infants <29 weeks' gestation randomised to high (60%) or low (30%) oxygen for initial resuscitation after birth. IPD will be sought for all infants randomised for the purpose of meta‐analysis. We will employ a one‐stage random‐effects approach to IPD meta‐analysis. Potential heterogeneity and the differential effect of high or low oxygen will be explored through subgroup and interaction analyses. The primary outcome of this study is all‐cause mortality prior to hospital discharge. There will be a follow‐up analysis of neurodevelopmental outcomes once available.Results/Conclusion: The results of neonatal outcomes at hospital discharge are expected by 2025, and neurodevelopmental outcomes by 2027.